Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by bfwon Mar 07, 2018 2:07pm
203 Views
Post# 27677253

RE:RE:RE:RE:RE:RE:RE:RE:RE:Analyst reports?!

RE:RE:RE:RE:RE:RE:RE:RE:RE:Analyst reports?!
jfm1330 wrote: As always the market is not giving much in advance to Thera. Skepticism is still there because of its history. This stock has been at 13.50$ many years ago and it fell down to pennies. It is hard to totally escape your history. If it would not be called Thera it would already be at 20$ just on the huge profit potential, but its called Thera. I think the company is near the time it will finally escape its history, but we are not there yet. This day will be linked to real profits. The old "show me the money" thing. As I said many times here, not only will it beat its history, but one day it will become overvalued. That's the way these markets work. So much is based on trust and for some, this incredible Ibalizumab deal and the approval are still not enough. They want to see the money.


Agreed, but the market will also be keeping an eye on Taimed this time around.

Investors in Taimed are not jaded and may push it quite high.

The arb opportunity will surely be exploited by someone with TH....evenutally.

bfw
Bullboard Posts